Nifural, 200 mg capsules 16 pcs
€11.40 €9.98
Pharmacotherapeutic group:
Antimicrobial agent-nitrofuran.
ATX code: A07AX03.
Pharmacological action
Pharmacodynamics
Nifuroxazide is an intestinal antiseptic, a 5-nitrofuran derivative, highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp; Clostridium perfingens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes. Resistant to Nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp, Pseudomonas spp.
Nifuroxazide presumably inhibits dehydrogenase activity and protein synthesis in bacterial cells. It does not cause the emergence of drug-resistant strains, also cross-resistance with other antibacterial drugs was not observed. The effectiveness of nifuroxazide does not depend on the pH in the intestinal lumen or on the sensitivity of microorganisms to antibacterial drugs. It does not affect the composition of normal bacterial flora of the digestive tract.
In acute bacterial diarrhea it restores intestinal eubiosis. In infection with enterotropic viruses prevents the development of bacterial superinfection.
Pharmacokinetics
Nifuroxazide is practically not absorbed from the digestive tract after oral administration and its antibacterial effect is exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestine: 20% unchanged and the rest chemically altered nifuroxazide.
Indications
Acute bacterial diarrhea, occurring without deterioration in general condition, increase in body temperature, or intoxication.
Pharmacological effect
Pharmacotherapeutic group:
antimicrobial agent – nitrofuran.
ATX code: A07AX03.
Pharmacological action
Pharmacodynamics
Nifuroxazide is an intestinal antiseptic, a derivative of 5-nitrofuran, highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp; Clostridium perfingens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp, Pseudomonas spp.
Nifuroxazide presumably inhibits the activity of dehydrogenases and protein synthesis in bacterial cells. It does not cause the emergence of drug-resistant strains, and cross-resistance with other antibacterial drugs has not been observed. The effectiveness of nifuroxazide does not depend either on the pH existing in the intestinal lumen or on the sensitivity of microorganisms to antibacterial drugs. Does not affect the composition of the normal bacterial flora of the digestive tract.
In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.
Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the digestive tract and exerts its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged, and the remaining amount of nifuroxazide is chemically modified.
Active ingredient
Nifuroxazide
Composition
1 capsule contains:
active ingredient:
nifuroxazide 100/200 mg;
excipients:
sugar (sucrose),
category “extra”
corn starch,
microcrystalline cellulose,
magnesium stearate;
hard gelatin capsule:
body and cap of the capsule – titanium dioxide,
iron oxide yellow,
gelatin.
Contraindications
Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug, sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, pregnancy, children under 3 years of age.
Manufacturer
Alium JSC, Russia
Manufacturer | Obolenskoe FP JSC, Russia |
---|---|
Medication form | capsules |
Brand | Obolenskoe FP JSC |
Other forms…
Related products
Buy Nifural, 200 mg capsules 16 pcs with delivery to USA, UK, Europe and over 120 other countries.